Last reviewed 2026-04-22 · How we verify

Bifidobacterium infantis 35624

Bifidobacterium infantis 35624 is a live probiotic bacterium that modulates the gut microbiota and intestinal immune function to reduce gastrointestinal symptoms.

Bifidobacterium infantis 35624 is a live probiotic bacterium that modulates the gut microbiota and intestinal immune function to reduce gastrointestinal symptoms. Used for Irritable bowel syndrome (IBS).

At a glance

Mechanism of action

This strain of beneficial bacteria colonizes the intestinal tract and produces metabolites that strengthen the intestinal barrier, reduce pathogenic bacteria, and modulate local and systemic immune responses. It has been shown to reduce visceral pain, bloating, and other symptoms associated with irritable bowel syndrome through these microbiota-mediated mechanisms.

Approved indications

• Irritable bowel syndrome (IBS)

Common side effects

• Abdominal discomfort
• Bloating
• Flatulence
• Headache

Key clinical trials

• Effect of Different Dietary Therapies on Intestinal Barrier Integrity in Patients With Irritable Bowel Syndrome (NA)
• Asacol Acute Diverticulitis(DIVA)Study (PHASE2)
• Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating (NA)
• Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome (PHASE3)
• Probiotics in GastroIntestinal Disorders (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bifidobacterium infantis 35624 CI brief — competitive landscape report
• Bifidobacterium infantis 35624 updates RSS · CI watch RSS
• Procter and Gamble portfolio CI